Skip to main content
main-content

12.07.2018 | Original Article – Clinical Oncology | Ausgabe 9/2018

Journal of Cancer Research and Clinical Oncology 9/2018

The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 9/2018
Autoren:
Jie Yang, Yuan Zhang, Xiaoting Sun, Aaron M. Gusdon, Nan Song, Linsong Chen, Gening Jiang, Yueye Huang
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00432-018-2702-9) contains supplementary material, which is available to authorized users.
Jie Yang, Yuan Zhang, and Xiaoting Sun have contributed equally to this work.

Abstract

Purpose

This study aimed to investigate the prognostic value of different organs metastases in patients with non-small cell lung cancer (NSCLC) and its most common subtypes.

Methods

We identified 45,423 NSCLC cases (25,129 men and 20,294 women) between 2010 and 2013 with distant metastases, with complete clinical information obtained from the surveillance, epidemiology, and end results (SEER) database.

Results

Bone and liver were the most and the least common metastatic sites with rates of 37.1 and 16.8%, respectively. The mortality rates associated with bone, brain, liver, lung metastases, and multiorgan metastases (MOM) were 73.2, 72.7, 78.3, 65.4, and 77.5%, respectively. Kaplan–Meier analyses demonstrated that patients with MOM and liver metastasis had the worst survival. Compared with NSCLC cases with other organ metastasis, but without the four organs metastasis, hazard ratios (HRs) for lung, bone, brain, and liver metastases, and MOM were 0.906 (95% CI 0.866–0.947), 1.276 (95% CI 1.225–1.330), 1.318 (95% CI 1.260–1.379), 1.481 (95% CI 1.388–1.580), and 1.647 (95% CI 1.587–1.709), respectively. Similar results were obtained for adenocarcinoma (AD) cases.

Conclusions

The mortality risk is highest with MOM and liver metastasis followed by bone, brain, other organ, and lung metastases in NSCLC and AD which is the most common variant for NSCLC. These results will be helpful for pre-treatment evaluation regarding the prognosis of NSCLC patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 20 KB)
432_2018_2702_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2018

Journal of Cancer Research and Clinical Oncology 9/2018Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise